153 related articles for article (PubMed ID: 10627926)
1. Immunotherapy of uveal melanoma.
Ksander BR; Chen PW
Dev Ophthalmol; 1999; 30():220-30. PubMed ID: 10627926
[No Abstract] [Full Text] [Related]
2. Immunotherapy of uveal melanoma.
Bosch JJ
Dev Ophthalmol; 2012; 49():137-149. PubMed ID: 22042018
[TBL] [Abstract][Full Text] [Related]
3. [Immunotherapy of uveal melanoma: vaccination against cancer. Multicenter adjuvant phase 3 vaccination study using dendritic cells laden with tumor RNA for large newly diagnosed uveal melanoma].
Schuler-Thurner B; Bartz-Schmidt KU; Bornfeld N; Cursiefen C; Fuisting B; Grisanti S; Heindl LM; Holbach L; Keserü M; Knorr H; Koch K; Kruse F; Meiller R; Metz C; Meyer-ter-Vehn T; Much M; Reinsberg M; Schliep S; Seitz B; Schuler G; Süsskind D; Viestenz A; Wagenfeld L; Zeschnigk M
Ophthalmologe; 2015 Dec; 112(12):1017-21. PubMed ID: 26602097
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy of Uveal Melanoma: Vaccination Against Cancer.
Kummer M; Schuler-Thurner B
Methods Mol Biol; 2017; 1499():273-278. PubMed ID: 27987156
[TBL] [Abstract][Full Text] [Related]
5. Tumor-Immune interactions: implications for cancer therapy.
Tham M; Abastado JP
Cell Cycle; 2015; 14(9):1347-8. PubMed ID: 25894850
[No Abstract] [Full Text] [Related]
6. Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies.
Komatsubara KM; Carvajal RD
Curr Oncol Rep; 2017 Jul; 19(7):45. PubMed ID: 28508938
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy for Uveal Melanoma.
Breazzano MP; Milam RW; Batson SA; Johnson DB; Daniels AB
Int Ophthalmol Clin; 2017; 57(1):29-39. PubMed ID: 27898611
[No Abstract] [Full Text] [Related]
8. The newest treatments for uveal melanoma.
Luke JJ
Clin Adv Hematol Oncol; 2019 Sep; 17(9):490-493. PubMed ID: 31549969
[No Abstract] [Full Text] [Related]
9. Update on Metastatic Uveal Melanoma: Progress and Challenges.
Spagnolo F; Picasso V; Spano L; Tanda E; Venzano C; Queirolo P
BioDrugs; 2016 Jun; 30(3):161-72. PubMed ID: 27000042
[TBL] [Abstract][Full Text] [Related]
10. Recent breakthroughs in metastatic uveal melanoma: a cause for optimism?
Sacco JJ; Kalirai H; Kenyani J; Figueiredo CR; Coulson JM; Coupland SE
Future Oncol; 2018 Jun; 14(14):1335-1338. PubMed ID: 29741103
[No Abstract] [Full Text] [Related]
11. Adoptive T cell immunotherapy of human uveal melanoma targeting gp100.
Sutmuller RP; Schurmans LR; van Duivenvoorde LM; Tine JA; van Der Voort EI; Toes RE; Melief CJ; Jager MJ; Offringa R
J Immunol; 2000 Dec; 165(12):7308-15. PubMed ID: 11120866
[TBL] [Abstract][Full Text] [Related]
12. [Study of the lymphocyte blast transformation reaction as a criterion of prognosis in the outcome of treatment of uveal melanoblastomas].
Kotelianskiĭ EO
Oftalmol Zh; 1986; (7):407-9. PubMed ID: 3493458
[No Abstract] [Full Text] [Related]
13. Rationale for Harnessing the Abscopal Effect as Potential Treatment for Metastatic Uveal Melanoma.
Batson SA; Breazzano MP; Milam RW; Shinohara E; Johnson DB; Daniels AB
Int Ophthalmol Clin; 2017; 57(1):41-48. PubMed ID: 27898612
[No Abstract] [Full Text] [Related]
14. MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells.
Bosch JJ; Thompson JA; Srivastava MK; Iheagwara UK; Murray TG; Lotem M; Ksander BR; Ostrand-Rosenberg S
Cancer Res; 2007 May; 67(9):4499-506. PubMed ID: 17483366
[TBL] [Abstract][Full Text] [Related]
15. Epidrugs in the Immunotherapy of Cutaneous and Uveal Melanoma.
Venza M; Visalli M; Catalano T; Beninati C; Teti D; Venza I
Anticancer Agents Med Chem; 2017; 17(2):190-205. PubMed ID: 27109020
[TBL] [Abstract][Full Text] [Related]
16. [MBD4 inactivation induces a new mutator phenotype in cancers].
Rodrigues M; Mobuchon L; Houy A; Derrien AC; Stern MH
Bull Cancer; 2018 Sep; 105(9):736-737. PubMed ID: 30032956
[No Abstract] [Full Text] [Related]
17. Adjuvant Dendritic Cell Vaccination in High-Risk Uveal Melanoma.
Bol KF; van den Bosch T; Schreibelt G; Mensink HW; Keunen JE; Kiliç E; Japing WJ; Geul KW; Westdorp H; Boudewijns S; Croockewit SA; van Rossum MM; de Goede AL; Naus NC; van der Graaf WT; Gerritsen WR; de Klein A; Punt CJ; Figdor CG; Cohen VM; Paridaens D; de Vries IJ
Ophthalmology; 2016 Oct; 123(10):2265-7. PubMed ID: 27476772
[No Abstract] [Full Text] [Related]
18. Uveal Melanoma: Identifying Immunological and Chemotherapeutic Targets to Treat Metastases.
Jager MJ; Dogrusöz M; Woodman SE
Asia Pac J Ophthalmol (Phila); 2017; 6(2):179-185. PubMed ID: 28399339
[TBL] [Abstract][Full Text] [Related]
19. Anthropometry in the immunotherapy of cutaneous and ocular melanomas.
Săftescu S; Munteanu M; Popovici D; Dragomir R; Dărăbuș MD; Negru AG; Negru ȘM
Rom J Ophthalmol; 2020; 64(2):190-194. PubMed ID: 32685786
[TBL] [Abstract][Full Text] [Related]
20. [Characteristics of the immune status of patients with uveal melanoma during the performance of organ-preserving treatment].
Maletskiĭ AP; Vit VV; Vanichkin AA
Oftalmol Zh; 1989; (6):341-6. PubMed ID: 2622598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
